Cue Biopharma Inc CUE

$25.57 +0.32 (1.27%)

Valuation

Market cap
183,426,000
Revenue TTM
$27,470,000
Net income TTM
$-26,600,000
PE ratio
0.00
Forward PE
—
Profit margin
-96.83%
Debt to equity
0.00

Trading

Volume
157,000
Avg volume
296,264
Day's range
$24.67 – $25.92
Shares out
7,264,000
Stochastic %K
13%
Beta
2.61
Analysts
Strong Sell
Price target
$81.02

Price

Company profile

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead au...

Show more

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 949 2680
Website
https://www.cuebiopharma.com
Address
40 Guest Street, Boston, United States

Latest news

Stocktwits

daprinta Sep 30, 7:49 PM
$CUE there will be more data results shortly…The $50MM pipe was led by Cormorant and Threadneedle before the data. I would assume they would want to put more money in before the next data. They invested at $33 no warrants! Largest shareholders sold 0 shares…w/+data it goes to $60-70…(it was in $60’s pre-mkt last wk)… soon there after I believe a partnership or an outright acquisition! Continue to buy here & feeling extremely confident 😎
0 replies
daprinta Sep 30, 1:34 PM
$CUE continue to nibble on more stock in $25-26 range…holding support & still grossly underrated & undervalued!
0 replies
BanditQ Sep 24, 5:21 PM
$CUE a cuppa weeks left
0 replies
tealeaves Sep 23, 2:19 PM
$CUE
0 replies
Quantumup Sep 23, 11:16 AM
Morgan Stanley⬆️ $CLDX's PT to $57 from $50,⬆️PoS for barzol' in CSU and CIndU to 85%, and risk adj'd peak sales to $1.7B while keeping an Overweight rating. $NVS $CUE RHHBY SNY - REGN SPRY AQST AZN IFRX Here's what Morgan Stanley said in its note: https://x.com/Quantumup1/status/2102718678793957738?s=20
0 replies
Jwhig Sep 22, 8:14 PM
$CUE file:///var/mobile/Library/SMS/Attachments/57/07/7AE8017F-3516-49C5-9B98-2C2535C502F8/Lucid%20Capital%20Markets%20LLC%20CUE%20Celldex%20Phase%203%20Strengthens%20the%20Case%20for%20an%20Undervalued.pdf Target 4X growth in 12 months and 15 X ultimate evaluation gap!
1 replies
Atgv Sep 22, 7:43 PM
$CUE see this stock has a pattern I swung traded this 3 times with an average gain of 10%
0 replies
FlashMcGash Sep 22, 4:59 PM
$CUE looks like capitulation.. quickly went to 25.50 then bounced.
0 replies